The price of IGM Biosciences Inc (NASDAQ: IGMS) closed at $8.68 in the last session, down -0.34% from day before closing price of $8.71. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 592532 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at IGMS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.18 and its Current Ratio is at 8.18. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on February 09, 2024, Upgraded its rating to Outperform and sets its target price to $21 from $9 previously.
On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $8.
H.C. Wainwright Downgraded its Buy to Neutral on December 07, 2023, whereas the target price for the stock was revised from $11 to $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 14 ’24 when Schwarzer Fred sold 4,182 shares for $10.17 per share. The transaction valued at 42,533 led to the insider holds 216,651 shares of the business.
Tahir Misbah sold 2,543 shares of IGMS for $25,864 on Mar 14 ’24. The CHIEF FINANCIAL OFFICER now owns 90,418 shares after completing the transaction at $10.17 per share. On Mar 14 ’24, another insider, Takimoto Chris H, who serves as the CHIEF MEDICAL OFFICER of the company, sold 2,535 shares for $10.17 each. As a result, the insider received 25,782 and left with 94,388 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGMS now has a Market Capitalization of 510.27M and an Enterprise Value of 213.10M. For the stock, the TTM Price-to-Sale (P/S) ratio is 239.58 while its Price-to-Book (P/B) ratio in mrq is 2.51. Its current Enterprise Value per Revenue stands at 100.05 whereas that against EBITDA is -0.84.
Stock Price History:
Over the past 52 weeks, IGMS has reached a high of $17.78, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is 11.92, while the 200-Day Moving Average is calculated to be 8.66.
Shares Statistics:
According to the various share statistics, IGMS traded on average about 284.60K shares per day over the past 3-months and 275.01k shares per day over the past 10 days. A total of 33.18M shares are outstanding, with a floating share count of 20.81M. Insiders hold about 64.60% of the company’s shares, while institutions hold 37.77% stake in the company. Shares short for IGMS as of Feb 29, 2024 were 4.51M with a Short Ratio of 15.84, compared to 4.69M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.68% and a Short% of Float of 29.13%.
Earnings Estimates
The company has 9 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.83 for the current quarter, with a high estimate of -$0.75 and a low estimate of -$0.96, while EPS last year was -$1.33. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.61 and low estimates of -$0.91.
Analysts are recommending an EPS of between -$2.82 and -$3.39 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is -$2.88, with 8 analysts recommending between -$2.04 and -$3.48.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $760k. It ranges from a high estimate of $1M to a low estimate of $570k. As of the current estimate, IGM Biosciences Inc’s year-ago sales were $1.64M, an estimated decrease of -53.70% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $780k, an increase of 74.10% over than the figure of -$53.70% in the same quarter last year. There is a high estimate of $1M for the next quarter, whereas the lowest estimate is $700k.
A total of 9 analysts have provided revenue estimates for IGMS’s current fiscal year. The highest revenue estimate was $3.42M, while the lowest revenue estimate was $2.9M, resulting in an average revenue estimate of $3.04M. In the same quarter a year ago, actual revenue was $2.13M, up 42.70% from the average estimate.
